Imodium

Loperamide Hydrochloride, the active ingredient in Imodium, is an antidiarrheal presented as an oral tablet for oral use. It reduces the frequency and urgency of watery stools in acute and chronic diarrhea, including travel‑related cases, and is indicated for use in adults and children over two years of age. It is available without prescription in the EU.

GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing, regulatory compliance and reliable global distribution.

Imodium is an antidiarrheal that acts on the gastrointestinal tract to control excess stool output in several diarrheal conditions.

Acute nonspecific diarrhea: decreases stool frequency and improves consistency in short‑term episodes. Chronic diarrhea associated with inflammatory bowel disease: helps manage persistent loose stools when disease activity is controlled. Travelers' diarrhea: provides symptomatic relief for diarrhea acquired during travel to high‑risk regions.

Common Side Effects: - Constipation: reduced bowel movements or hard stools. - Nausea: mild stomach upset. - Abdominal cramps: intermittent discomfort. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Drowsiness: mild sedation.

Serious or Rare Side Effects: - Severe constipation or fecal impaction: risk of bowel obstruction. - Toxic megacolon: rare but life‑threatening colonic dilation. - Allergic reactions: rash, itching, or swelling. - Cardiac arrhythmia: QT prolongation especially with high doses or interacting drugs. - Central nervous system depression: especially when combined with other opioids.

Before using Imodium, consider the following safety measures. - Do not exceed recommended dose: follow prescriber or label instructions. - Avoid use in bacterial enterocolitis: may worsen infection. - Use with caution in hepatic impairment: reduced metabolism may increase exposure. - Consult healthcare provider before use in children under two years: safety not established. - Avoid concomitant use with strong CYP3A4 inhibitors: risk of increased cardiac toxicity. - Store at ambient temperature: keep in the original pack, protect from moisture.

Loperamide may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise loperamide levels and precipitate cardiac toxicity. - Co‑administration with other opioids: may cause additive central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): may modestly increase plasma concentrations. - P‑glycoprotein inhibitors (e.g., quinidine, verapamil): can affect drug transport and raise levels. - Anticholinergic agents: may enhance constipation risk.